There’s something about the whole idea of eradicating polio that grabs the imagination,” says Aidan O’Leary.
“Most people talk about making steps toward achievements, and it’s almost always into the never-never. Eradication is a zero-sum game; anything short of zero is failure. You keep getting closer and closer, but ultimately the only number that actually matters is zero.”
Although Aidan, the polio eradication director for the World Health Organisation, is speaking from his home in Galway, against the verdant backdrop of western Ireland, his focus is on war-torn Afghanistan and the parched and dusty plains of Pakistan — the last two places on the planet where wild polio still thrives.
We have an agreement with the Taliban to conduct mosque-to-mosque campaigns, which we hope we’ll be able to initiate in the coming months.”
Even during a pandemic, even as grim realities confront him, Aidan conveys a sense of optimism about the possibility of finally eradicating polio.
“Particularly in the days of COVID-19, there is something that really resonates about snuffing out a highly communicable infectious disease,” he says.
“As COVID has taken off, it has also led a lot of people to better understand why now is the time to finish this job with polio.”
Yet Aidan’s optimism is shaded with a sense of urgency and pragmatism.
“There is absolutely no case for complacency here,” he says. “What is really important is that we double down on reaching the persistently missed children who are a top priority for our programme.”
Aidan, who began his tenure as WHO’s polio chief in January, came into the job knowing the terrain well.
He formerly led UNICEF’s polio eradication efforts in Pakistan and was the head of the United Nations Office for the Coordination of Humanitarian Affairs in Afghanistan, Iraq, Syria, and Yemen, organizing the UN’s emergency response during crises.
Aidan is the polio eradication director for the World Health Organisation formerly led UNICEF’s polio eradication efforts in Pakistan.
Aidan says he understands the difference Rotary can make — both in a community and in the global fight against polio. In Galway, a local tradition involves kicking the limestone wall at the end of a two-mile stroll on the Salthill Promenade along Galway Bay (the reason for doing so has been lost in the mists of time).
In 2012, Aidan explains, the Rotary Club of Galway-Salthill installed on that wall a box that bears the slogan “Small Change, Big Impact” and encourages walkers to leave a small donation, with all money collected going to local charities and institutions.
In July, weeks before the dramatic turn of events in Afghanistan, Aidan joined Rotary magazine senior staff writer Diana Schoberg and Dave King, editor of Rotary magazine for Rotary International in Great Britain and Ireland, on a Zoom call to discuss the new strategy of the Global Polio Eradication Initiative (GPEI) and the new polio vaccine, and how they will be used to eradicate polio — once and for all.
What is the latest update on wild poliovirus?
The numbers are extremely encouraging. We’ve gone over a very bumpy road during the last two years. We had a five-fold increase in cases between 2018 and 2019, when we saw 176 cases, and we had 140 cases in 2020. But we’ve recorded just two cases this year [as of 27 July] — one each in Afghanistan and Pakistan. [Both cases were in January.]
The particularly encouraging part right now is that the programme has a very elaborate network of environmental testing sites for sewage — almost 100 sites in Afghanistan and Pakistan that cover all of the major population centres.
In 2020, almost 60% of the monthly test samples came back positive for poliovirus. This year to date, that percentage is probably around 15%. We have been unable to detect any wild poliovirus in Afghanistan since 23 February, and we’ve seen just five isolates in Pakistan since 12 April.
Why do you think that is? Given that some polio immunisation campaigns had to be suspended last year, you’d think the numbers would have gone in the other direction. Is it because so many elements of society were shut down due to the pandemic?
While conditions in 2020 were certainly adverse both for surveillance and for the campaign operations, there are two areas that are helping us this year. One is reduced mobility — both within Afghanistan and Pakistan, and across the borders.
When you look particularly at the experience in India, with the explosion of COVID cases in the first and second quarters of 2021 — and what were some very shocking images of funeral pyres — I believe that the drop in mobility has had an impact. There has also been a change in social norms, very simple things like social distancing and hand washing. Maybe that has made some impact, as well. But those are short-term changes.
With the conflict in Afghanistan, we don’t believe that the benefits we’re seeing from reduced mobility will continue indefinitely. We need to continue to prepare for the possibility of large-scale displacements across borders. We need to grab the opportunity that we have.
Now we’re coming into the high season for polio transmission, so we’ll continue to wait and see. There’s certainly no complacency from our programme.
“In 2020, almost 60% of the monthly test samples came back positive for poliovirus. This year to date, that percentage is probably around 15%.”
Vaccines are on everyone’s mind because of COVID. Has that affected acceptance of the polio vaccine?
For me, the more fundamental issues in Afghanistan and Pakistan centre around household and community confidence and trust. If you get the basics of that right, you are 80% to 90% there. The challenge has always been reaching the other 10% to 20%.
The key issue is broader — the marginalisation of communities. That’s not something that can be addressed just at the household and community level. It requires a systemic engagement to try to make sure that we properly understand the community’s actual needs and then that we connect those dots in a more reliable way.
The single most important relationship that the programme has is between a frontline vaccinator and the caregiver who answers the knock at the door.
That caregiver is usually the mother, and what’s really important for our success is that the frontline vaccinator is a local woman who is well-trained and motivated to do what she’s doing. If that relationship of confidence and trust is developed, then you’re able to vaccinate all of the children inside the house.
Because of the suspension of house-to-house vaccination campaigns in 2018 in areas of Afghanistan controlled by the Taliban, more than 3 million children routinely miss vaccinations. Do you think that polio eradication is possible while the security situation in Afghanistan is so unpredictable?
We continue to speak with all parties. Our priority is the protection of children, and that requires engaging with all stakeholders. We have an agreement with the Taliban to conduct mosque-to-mosque campaigns, which we hope we’ll be able to initiate in the coming months. In some cases, we’ll be reaching children for the first time in several years. We’d like to build on those opportunities toward resuming house-to-house vaccination campaigns.
We don’t have an all-or-nothing situation. Let’s seize the opportunity to reach 40% to 50% coverage before we start talking about 100%. Will the campaigns in July and August be perfect? No. They’re taking place against the backdrop of a growing full-scale conflict, so we have to make sure that we find appropriate ways of making that work.
There will be risks. Eight frontline workers were killed in eastern Afghanistan earlier this year in various targeted killings. In these contested areas, the de facto authorities on the ground shift. We need to make sure that we navigate these areas as sensitively as we possibly can.
“The single most important relationship that the programme has is between a frontline vaccinator and the caregiver who answers the knock at the door.”
We are also working on financing essential immunisation coverage [universal access to all relevant vaccines], particularly in the provinces of the southern region of Afghanistan. We recognize that it’s not just a polio gap. There’s a much broader gap.
The other point that I would highlight is the importance of the surveillance system. Although we have not been able to reach all children with vaccinations, our surveillance system is continuing to pick up all the acute flaccid paralysis cases.
There is a basic system in place that allows us to properly understand what’s going on. We want to build incrementally and in a sustainable way to make sure that we have access in all of these areas for the purposes of our immunisation programmes.
What about in Pakistan, where 81% of the cases are among the Pashto-speaking population, who make up 15% of the overall population. Why are the cases so concentrated within that group, and what is the programme planning to do to address it?
It’s often presented as a vaccine acceptance issue, but I think it’s much broader than that. Because of economic migration, among other reasons, you have this massive influx of Pashto-speaking people from across Afghanistan and Pakistan into Karachi.
You’re seeing this huge explosion of settlements — formal, informal, and everything in between. These settlements tend to be highly underserved. There can be issues between the state and provincial administrations and these minority communities. There’s a wider issue around community acceptance, confidence, and trust.
The polio eradication programme is one of the few programmes that reaches these communities, but their needs go way beyond polio vaccines, including clean water and sanitation, nutrition, basic health services, and education.
So when you are trying to access these informal settlements, you have this big residue of issues that polio essentially becomes the proxy for.
These issues are not strictly within the control of our programme, but we recognise that to build the acceptance and trust of these communities, we’re going to have to make a much more sustained effort than we perhaps may have been doing in the past. The idea on our side is to move from patchy and ad hoc initiatives to something much more comprehensive and systemic.
The new strategy talks about “zero-dose children.” What does that term mean?
Zero-dose refers to any child who has never had a vaccine. We want to make sure that they not only get the oral polio vaccines but also as many other essential immunisations as is feasible. It’s not just a question of a fixed, static target of high-risk children in core reservoirs — those areas with persistent wild poliovirus transmission. There is a rolling target that we have to stay on top of. We’re in a race against time with new-borns. There are between 7 and 8 million babies born every year in Pakistan. So we need to make sure that within the first months of those babies’ lives, we’re reaching as large a proportion of them as we possibly can.
What’s your best guesstimate of your target?
Every time we do a national immunisation campaign in Pakistan, which are house-to-house campaigns, we target more than 40 million children under age 5. When we go to Afghanistan, that number is between 9 million and 10 million. It continues to be very humbling to see what frontline workers are doing during a pandemic.
“Zero-dose refers to any child who has never had a vaccine. We want to make sure that they not only get the oral polio vaccines but also as many other essential immunisations as is feasible.”
We’re dealing with two issues here, aren’t we — wild poliovirus and the circulating vaccine-derived poliovirus. What is the difference between the two?
The wild poliovirus is essentially as its name describes. It’s the original of the species. It has evolved over centuries and millennia, and it has continued to evolve.
The oral polio vaccine contains a live but weakened virus, which can circulate among under-immunised or unimmunized populations for a long period of time, usually for years. And eventually, it can revert to a form that causes paralysis. That is circulating vaccine-derived poliovirus [cVDPV].
Viruses require an immunity gap. They need susceptible children. Anywhere there are zero-dose children, you’re going to find these diseases taking off. When we map where these children are, we keep coming back to the same locations again and again. That’s why we really have to double down and make sure that these zero-dose children are our very top priority to get covered by vaccination.
Globally, how widespread is cVDPV?
There have been 1,800 cases since 2016. Between 2018 and 2019, there was a tripling of cases, and then there was a further tripling between 2019 and 2020. The total number of cVDPV cases in 2020 was 1,103. So far in 2021 [as of 27 July], there have been 179 cases. We’ve seen real progress as immunisation campaigns have resumed. The number of countries with cases has decreased from 27 last year to just over a dozen.
These cases happen where children miss vaccinations. When children are fully vaccinated, cVDPV is not a problem. These cases are highly concentrated, with Afghanistan and Pakistan making up 40% of cases in 2020. If you look at the situation in Afghanistan, which was the country with the greatest number of cVDPV cases last year, more than 90% of those were concentrated in the areas that were inaccessible due to the Taliban banning house-to-house polio campaigns.
So again, the challenge for us is to protect through vaccination. You create a risk by not building up the immunity levels as high as they could or should be. As a programme, we are trying to get back to a stage where we’re going after the root cause of the problem — which means making sure that we are fully vaccinating all of these zero-dose children.
If there are two cases of wild poliovirus and more than 100 cases of cVDPV, which is the bigger concern?
We set ourselves two goals: The first is to eradicate the wild poliovirus, and the second is to interrupt the transmission of cVDPV. The wild poliovirus has proven to be the most elusive. We need to clear it once and for all. Afghanistan and Pakistan are the two countries where the two types co-circulate. We’ve seen very clearly that with the regular campaigns, we have been able to mop up cVDPVs to a pretty good extent. The wild poliovirus is a much more persistent challenge.
There is a new tool for tackling cVDPVs. How was that developed and what are you hoping to achieve?
Last November, WHO granted its first-ever emergency-use listing for a vaccine to the novel oral polio vaccine type 2 [nOPV2]. This is a vaccine that has been under development for almost 10 years. It’s as effective as the existing vaccines, but it has much greater genetic stability. That makes it less likely to regress to a form that can cause paralysis.
The Strategic Advisory Group of Experts on Immunisation has described it as the vaccine of choice for outbreaks [of cVDPV] moving forward. Countries that want to use the vaccine have to meet the criteria for initial use [regarding surveillance and safety monitoring].
We’ve seen a large number of campaigns implemented since March, with almost 50 million vaccines administered, and we’ve had no major adverse safety signals and no adverse signals on surveillance that would give rise to concern. We’re working to see if we can move from an initial-use phase to a wider-use phase, which would reduce some of the more onerous requirements, particularly around the surveillance system.
If you were a betting man, where would you put the odds that Afghanistan and Pakistan will become totally polio-free?
I would be pretty confident.
Our new strategy has a goal of interruption of circulation of all wild and circulating vaccine-derived poliovirus by no later than 2023, and certification of the world as wild polio-free by 2026.
An important point is that I find 2023 and 2026 mean nothing to people on the ground. I’ve spent 20 years in operations. When you talk about these three- and five-year strategies, people’s eyes glaze over. We need much more tangible targets, built quarter by quarter.
What keeps me awake at night is the risk if we’re not ruthlessly focused on that. We can generate big numbers, but are we actually getting the right children vaccinated with all of our efforts?”
What we set as a target for this particular quarter [July-September] is to open up the access dynamics in Afghanistan. We set targets, for instance, in relation to the move from initial use to wider use of nOPV2. We’re seeing very substantial progress in relation to that.
And that’s why, forget 2023, forget 2026 — focus on what we need to do this month, what we need to do next month, what we need to do the month after. Keep a rolling cycle of performance improvements, which is the absolute key toward making this goal.
In June, the Global Polio Eradication Initiative released a document titled “Delivering on a Promise: Polio Eradication Strategy 2022-2026.” Will it do as it says?
I do think it’s feasible to reach our set timelines and goals, and to deliver on what was laid out within them. We just have to be very honest about where the gaps are and what’s being done to close them. The eradication programme is not about achievements. It’s all about closing gaps: access gaps, surveillance gaps. We just keep going, going, going, and then suddenly you realise you’re there.
I’ll highlight two of the situations that I’ve dealt with in my career. I started working on polio eradication originally in January 2015 [as chief of polio eradication in Pakistan for UNICEF], and at that time Pakistan’s programme was described as a disaster by the Independent Monitoring Board.
In 2014, there were 359 global cases of wild poliovirus, of which 306 were in Pakistan. Two and a half years later, we were down to roughly three cases. I think we had a total of eight for the year. We worked our way through the challenges. It’s important to be ruthlessly focused on finding the critical path for eradication. So that was lesson No. 1.
With this job, when I started in January, I was asked why I was taking on this programme at this point in time. For me, it’s never daunting and it’s never impossible. The challenge is to understand where you are and then, concretely, what are the practical steps that you need to take. For me the big achievement last year was staying in the fight.
People sometimes underestimate what it meant to get the programme back up and running in the middle of the pandemic. There were very courageous decisions by governments and by frontline workers, as well as a whole range of other people.
A previous strategy was published in 2019. What wasn’t working, and how is the new strategy bringing in new ideas?
The epidemiology was going further and further away from zero, and then came the COVID pandemic, which was a pretty fundamental game changer. There was a real concern that the programme had lost its emergency orientation. There was also a recognition of the need to have a serious re-look at the broader-based community demands.
Another part is related to government ownership. It’s one thing for the GPEI to have its emergency orientation. But we also need that emergency orientation to be identified by governments.
One of the things that was very striking for me in Pakistan was the extent to which the National Emergency Operations Centre infrastructure was being used to support the pandemic response. There was a daily meeting on COVID with the top provincial leadership, the military, and the Ministry of Health.
All of the groups were reviewing real-time data, making decisions, and then having pretty robust accountability for follow-up actions. We want to convey the message that, though the magnitude of the polio emergency is not of the same scale as the COVID pandemic, we would strongly encourage that modus operandi.
The other piece that has to be strengthened is performance and risk management. We’ve talked about 2023 and 2026. But what are all the milestones? When you’re reviewing your performance, course corrections are fundamentally better when they’re done at the moment. We need to do that in a much more structured way, with key metrics.
“In 2014, there were 359 global cases of wild poliovirus, of which 306 were in Pakistan. Two and a half years later, we were down to roughly three cases.”
What thing are you most focused on? What keeps you up at night?
Seizing the opportunities that are in front of us. Keeping ruthlessly focused on persistently missed children. We have a lot of initiatives, but they aren’t equally effective.
What’s really important is that whether it’s campaigns, health camps, or routine immunisations — whatever we’re doing, is it helping us to vaccinate one more persistently missed child in a core reservoir? Are we making inroads with every single campaign, with every single activity we do, that are bringing us closer and closer to our goal?
What keeps me awake at night is the risk if we’re not ruthlessly focused on that. We can generate big numbers, but are we actually getting the right children vaccinated with all of our efforts?
What is your message to Rotary members?
I’ve been in this job now for six months. I’ve met with Rotarians virtually and in person across India, Africa, Pakistan, and Afghanistan. I haven’t detected any kind of diminution of commitment. There’s a very clear-eyed focus. The message is simple: A polio-free world is within reach. There is an opportunity, and now is the time to stay the course.
Strategic plan highlights
In June, the Global Polio Eradication Initiative launched a new strategic plan, “Delivering on a Promise: Polio Eradication Strategy 2022-2026,” with two goals: interrupting the transmission of wild poliovirus in the two remaining endemic countries (Afghanistan and Pakistan) and stopping outbreaks of circulating vaccine-derived poliovirus (cVDPV), which arise when the live virus used in the oral polio vaccine mutates back to a virulent form as it circulates among unimmunized and under-immunized populations.
Here’s how we’ll get there:
1
Political advocacy: Work with governments to generate greater urgency and accountability for timely and effective outbreak responses. Build personal relationships and increase trust with those at the national, provincial, and local levels to develop a better understanding of the benefits of the polio programme. Explore options to work around the ban on house-to-house vaccinations in parts of Afghanistan.
2
Community engagement: Build meaningful partnerships with high-risk communities disproportionately affected by polio, such as Pashto-speaking communities in Afghanistan and Pakistan. Create committees where community members can contribute to polio campaign planning and relay other health needs. Work with Pashto-speaking influencers, such as birth attendants and women’s groups, to develop a better understanding of how polio vaccinations can support their broader child care practices.
3
Improve operations: Strengthen campaigns by recruiting and training frontline workers who come from the local community, speak the local language, and are women. Ensure frontline workers have the supplies and security to do their jobs well and receive professional development opportunities. Adopt technical innovations such as digital mapping and mobile payments to workers. Deploy the recently approved novel oral polio vaccine type 2 (nOPV2) to fight outbreaks.
4
Integrate polio into health programmes: Reach zero-dose children in Afghanistan and Pakistan with all vaccines. Support the COVID-19 vaccine rollout. Make polio vaccines part of a broader health and basic services package that is developed in partnership with communities. Support health facilities in providing a dose of oral polio vaccine to new-borns.
5
Improve surveillance: To speed up outbreak responses, use technical innovations to get quicker results when testing for poliovirus in children with paralysis. Integrate polio surveillance into the surveillance systems for other vaccine-preventable diseases, such as measles and COVID-19.
Read the full report at polioeradication.org/gpei-strategy-2022-2026.
